Clinical Trial Update: 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment [Phase 1]

View source ↗

Summary

Phase 1 trial of the agent 506U78 in patients with hematologic cancers and kidney or liver impairment; the study has terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Myeloproliferative Disorders
• Plasma Cell Neoplasm

Drugs mentioned

• 506U78

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Status: TERMINATED